IRLAB A — IRLAB Therapeutics AB Share Price
0.000.00%
Last trade - 00:00- SEK531.65m
- SEK447.91m
- SEK5.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.59 | ||
| Price to Tang. Book | 7.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 93.63 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -128.76% | ||
| Return on Equity | -87.48% | ||
| Operating Margin | -3183.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 0.03 | n/a | 207.78 | 61.14 | 5.68 | 64.5 | n/a | 216.07% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Directors
- Anders Vedin CHM (77)
- Nicholas Waters CEO (57)
- Carola Lemne VCH (63)
- Viktor Siewertz CFO (48)
- Cecilia Tivert Stenberg FID (62)
- Peder Svensson CIO (57)
- Clas Sonesson CSO (58)
- Susanna Holm Waters OTH (53)
- Maria Jalmelid OTH (40)
- Joakim Tedroff OTH (58)
- Lars Adlersson IND (56)
- Eva Lindgren IND (69)
- Gunnar Olsson IND (66)
- Hans-Olov Olsson IND (78)
- Rein Piir IND (62)
- Lena Torelgard IND (56)
- John Wakely IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 13th, 2013
- Public Since
- February 28th, 2017
- No. of Employees
- 37
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 51,868,406
- Address
- Arvid Wallgrens Backe 20, GOETEBORG, 413 46
- Web
- https://irlab.se/
- Phone
- +46 317573800
- Contact
- Tove Bergenholt
- Auditors
- Ohrlings PricewaterhouseCoopers AB
Upcoming Events for IRLAB A
IRLAB Therapeutics AB Annual Shareholders Meeting
IRLAB Therapeutics AB Annual Shareholders Meeting
Q2 2024 IRLAB Therapeutics AB Earnings Release
Similar to IRLAB A
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
What is the IRLAB Therapeutics AB share price?
As of Today at 07:11 UTC, shares in IRLAB Therapeutics AB are trading at SEK10.25. This share price information is delayed by 15 minutes.
How has the IRLAB Therapeutics AB share price performed this year?
Shares in IRLAB Therapeutics AB last closed at SEK10.25 and the price had moved by -4.65% over the past 365 days. In terms of relative price strength the IRLAB Therapeutics AB share price has underperformed the FTSE Global All Cap Index by -12.65% over the past year.
What are the analyst and broker recommendations for IRLAB Therapeutics AB?
There is no consensus recommendation for this security.
What is the IRLAB Therapeutics AB dividend yield?
IRLAB Therapeutics AB does not currently pay a dividend.
Does IRLAB Therapeutics AB pay a dividend?
IRLAB Therapeutics AB does not currently pay a dividend.
When does IRLAB Therapeutics AB next pay dividends?
IRLAB Therapeutics AB does not currently pay a dividend.
How do I buy IRLAB Therapeutics AB shares?
To buy shares in IRLAB Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of IRLAB Therapeutics AB?
As of the previous close price of SEK10.25, shares in IRLAB Therapeutics AB had a market capitalisation of SEK531.65m.
Where are IRLAB Therapeutics AB shares listed?
Here are the trading details for IRLAB Therapeutics AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: IRLAB A
What kind of share is IRLAB Therapeutics AB?
Based on an overall assessment of its quality, value and momentum IRLAB Therapeutics AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a IRLAB Therapeutics AB share price forecast for 2024?
The analyst consensus target price for shares in IRLAB Therapeutics AB is SEK35.00. That is 241.46% above the last closing price of SEK10.25.
Analysts covering IRLAB Therapeutics AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK3.31 for the next financial year.
What is the trend in the IRLAB Therapeutics AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IRLAB Therapeutics AB. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +26.22%.
As of the last closing price of SEK10.25, shares in IRLAB Therapeutics AB were trading +1.92% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the IRLAB Therapeutics AB PE Ratio?
The IRLAB Therapeutics AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK10.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of IRLAB Therapeutics AB?
IRLAB Therapeutics AB's management team is headed by:
- Anders Vedin - CHM
- Nicholas Waters - CEO
- Carola Lemne - VCH
- Viktor Siewertz - CFO
- Cecilia Tivert Stenberg - FID
- Peder Svensson - CIO
- Clas Sonesson - CSO
- Susanna Holm Waters - OTH
- Maria Jalmelid - OTH
- Joakim Tedroff - OTH
- Lars Adlersson - IND
- Eva Lindgren - IND
- Gunnar Olsson - IND
- Hans-Olov Olsson - IND
- Rein Piir - IND
- Lena Torelgard - IND
- John Wakely - IND